Chemeleon has developed an innovative platform technology that enables rapid, accurate, and cost-effective diagnostics for a wide array of analytes, including drugs, proteins, and viruses. This technology operates in a sample-to-answer format, providing a colorimetric readout that is visible to the naked eye within minutes, eliminating the need for any specialized instruments or training. This decentralized testing capability allows for point-of-care diagnostics to be extended beyond traditional clinical settings, making it accessible in various environments where immediate results are crucial.

One of the primary applications of Chemeleon's technology is in the detection of acute myocardial infarction (AMI). Their colorimetric diagnostic tool can deliver results in under two minutes, offering a straightforward yes or no readout without the need for instrumentation. This rapid detection is vital, as timely identification of AMI can significantly improve patient outcomes, reduce complications, and enhance the efficiency of emergency department workflows. By facilitating quick triage and minimizing waiting times, Chemeleon's diagnostic solutions aim to transform the landscape of emergency medical care.

United States

Chemeleon has created a platform technology for the rapid, instrument-free, detection of chemical compounds in the field, obviating the need for slow, complex, and expensive lab analysis.  Our sensor materials combine highly selective molecular receptors with colorimetric nanomaterial reporters to provide an autonomous and inert means of optically detecting hazardous chemicals in virtually any environment, from clinical to third-world settings.

Chemeleon

Company Details